Lilly has reported clinical success with Baricitinib (JAK inhibitor) in patients with alopecia. Two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth with baricitinib compared to placebo. https://t.co/D0GE2cSzDZ